Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
NCT04410913 · Keith Heinzerling
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Feasibility: Recruitment Rate
Measured over Week 10
Feasibility: Retention Rate
Measured over week 10
Tolerability: Number of Visual Healing segments viewed by participants
Measured over Week 7
Safety/Tolerability: number of Adverse Events
Measured over Week 14
Safety: Systolic Blood Pressure
Measured over Week 14
Safety: Diastolic Blood Pressure
Measured over Week 14
Safety: Heart rate
Measured over Week 14
Tolerabilty: Spielberger State-Trait Anxiety Inventory -Short Form (STAI-SF) mean score
Measured over Week 14
Safety: Challenging Experience Questionnaire (CEQ)
Measured over Week 14
Safety: Questionnaire for Psychotic Experiences
Measured over Week 14
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Pacific Treatment & Research in Psychedelics | Santa Monica | California | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04410913 on ClinicalTrials.gov →
Last updated in the registry 2023-01-17. Registry records change; this page reflects the data build of 2026-08-25.
Related